Rentschler Biopharma Nukleus Building Laupheim

Welcome to Rentschler Biopharma

As a leading Contract Development and Manufacturing Organization (CDMO), we focus exclusively on our clients' projects – and on creating value sustainably. Our vision is to advance medicine to save lives. Together.

Learn more

We offer full-service solutions for bioprocess development and manufacturing of high-quality biopharmaceuticals. 

Our strength lies in our experience with highly complex molecules. Discover how we can support your project. From concept to market.

Our Track Record

With more than 50 years of industry experience, we at Rentschler Biopharma are highly qualified experts in the field of biopharmaceuticals. We share your passion for innovation and excellence and set standards in the biopharmaceutical industry.

160+
60%
> 130

NEWS

Find out how we are helping to shape the future of biopharmaceuticals. Visit us at the leading industry trade fairs and get to know our team personally. Our news section informs you about the latest developments at our company.

Learn more

Thursday, May 2, 2024

Rentschler Biopharma Appoints Patrick Cushing as VP Operations for U.S. Subsidiary

Monday, April 29, 2024

Creative Disruption Forum on Cell & Gene Therapies: Making your company more investable

Thursday, April 11, 2024

Interview: “We see the trend towards personalized medicine not as temporary, but permanent”

Rentschler Biopharma news Stevenage UK
Wednesday, March 27, 2024

Article: Inside Rentschler Biopharma’s Stevenage Site for Advanced Therapies

Rentschler Biopharma News Benedikt von Braunmühl
Friday, March 22, 2024

Article: Digital transformation is a must - how digitalization will change CDMOs

Rentschler Biopharma news interview with Yatindra Tirunagari use of AI in the ATMP industry
Thursday, March 21, 2024

On-demand Webinar: The Use of Digital Technologies in CGT Manufacturing

Wednesday, March 13, 2024

Rentschler Biopharma takes home the Gold in 20th Annual Team Massachusetts Economic Impact Awards

Rentschler Biopharma News single-use 2000 liters
Wednesday, March 6, 2024

Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023

Regulatory compliance is particularly important for US and EU in clinical and commercial stage. Rentschler Biopharma has the knowledge to get into local markets quickly and risk-free.

— Director of a Biopharma company

Careers

As an independent family-owned company, Rentschler Biopharma employs approximately 1,400 people at its headquarters in Laupheim, Germany and a second site in Milford, MA, USA. A third site based in Stevenage, UK, specializes in cell and gene therapies. What unites us is our passion for what we do.

Our Job Openings

Rentschler Biopharma CDMO become part of the team

Get in Touch

Contact us now to discuss your needs and find solutions together.

*Required Fields